The Singulex Erenna Immunoassay system can detect proteins at the femtogram (10−15g) level, allowing measurements of extremely low levels of protein, the contract research organisation (CRO) said.
The tool is used in pharmacokinetic studies to measure biomarkers and evaluate the immune response to large molecule drugs. Detecting very small levels of protein in biopharmaceuticals can be a challenge.
“The Erenna immunoassay system, powered by Singulex’s SMC technology, provides unprecedented quantification of protein targets at low and high abundance, providing a complete data set for a sponsor to make informed decisions and accelerate program success,” said Paul Wheeler, VP, Life Science Sales and Marketing at Singulex.
“Eurofins is a trusted outsourcing partner for many in the pharma industry, and we are pleased that they have added the Erenna system to their Bioanalytical Lab Services offering.”
“Eurofins Bioanalytical Serrvices has already partnered with several of our clients to develop and transfer novel methods on the Erenna system.” said Dr Jim Hulse, General Manager of Eurofins Bioanalytical Services. “We look forward to working with additional users of the platform as we begin offering services using the existing biomarker assay kits available from Singulex.”
Bio-outsourcing is on the rise, reports show, with analytical testing – such as assays – topping the list of tasks pharma companies are willing to send out of house.